Skip to content
Biodatica
Start free

Investigator

Harvey D Homan

METASTX LLC · funded by NCI

Companies
1

Resolved onto their grants.

Grants
1

Federal awards on file.

Non-dilutive funding
$400k

Summed across those awards.

First award
Jul 1, 2025

On this record.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R43

    Epithelial-Mesenchymal Transition Signature Markers (EMTsm) with Machine Learning-Based Analysis as a Predictor of Metastatic Prostate Cancer

    $400k

    Jul 1, 2025NCIMETASTX LLCNIH RePORTER · 11068839 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources